Download now: life sciences - whitepaper: building an investable ip portfolio
​

Make your bio(pharma) IP investment ready

​
March 22, 2026

Download PDF

Table of contents
  • Toc Heading
  • Toc Heading
Gareth Probert
Partner, UK and European Patent Attorney, UPC Representative
Rob Barker
Partner, UK and European Patent Attorney, Design Attorney, UPC Representative
Tim Belcher
Partner, UK and European Patent Attorney, UPC Representative

Whether you’re scaling or planning your next strategic step, these sessions will share practical insights to help future‑proof your IP and strengthen your investment story.

Episode 1: How to build a resilient IP portfolio in the (bio)pharma sector

How you structure and protect intellectual property can be critical to securing investment in the biopharma sector. In this first episode of EIP’s LinkedIn Live series, our biopharma IP experts examine what investors look for in an investment‑ready biopharma IP portfolio, and how companies can position their patent strategy to support funding, partnerships, and long‑term value creation.

Gareth Probert, Head of Biopharma & Chemistry, and Tim Belcher, Partner in EIP’s Biopharma team, focus on three core pillars that consistently influence investor due diligence and valuation: who owns the IP, what should be protected, and when patent applications should be filed.
‍

Episode 2: Strategic IP moves to consider when preparing for an investment round

In this second episode of EIP’s LinkedIn Live series, Tim Belcher and Rob Barker explore the strategic IP decisions biopharma companies should make ahead of investment rounds. From aligning patent strategy with investor expectations to managing disclosures, due diligence, freedom‑to‑operate, and data rooms, the session outlines practical steps to reduce risk, build credibility, and position IP as a core driver of valuation and deal success.

‍

Episode 3: A forward look at the 2026 (bio)pharma landscape and what it means for your business and IP strategy

In the final episode of EIP’s LinkedIn Live series, Gareth Probert and Robert Barker explore what the year ahead holds for biopharma investment and IP strategy. The discussion highlights renewed optimism and increasing deal activity as the sector emerges from a period of reduced investment. With major pharmaceutical companies facing significant patent cliffs, attention is shifting towards external innovation, particularly later‑stage and proof‑of‑concept assets that can replenish pipelines quickly.

The Latest Thought Leadership pieces in the Content Hub

See all articles

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

​
Interested in a career at EIP?

View Open Roles

Heading
This is some text inside of a div block.
This is some text inside of a div block.
​

Latest Insights

Showing 0 of 100
Filters
What are the options if you want to be able to use the UPC?
03 November 2022
All unitary patents fall within the competence of the Unified Patent Court (UPC). Additionally, classical validations of European Patents in states which have ratified the UPC agreement are within...
#
Patenting
​
What is the Unified Patent Court?
01 November 2022
The Unified Patent Court ("UPC") is a new pan-European court which opened for business on 1 June 2023. It adjudicates disputes relating to the new Unitary Patents and also to existing and future...
#
Litigation
​
What is the Unitary Patent and how do I get one?
01 November 2022
The Unitary Patent (UP) is a single patent right, obtained via the European Patent Office, covering all EU Member States which have ratified the agreement at the patent grant date, and is subject to...
#
Patenting
​
How does the opt-out work?
01 November 2022
The Unified Patent Court (UPC) will ultimately be responsible for all litigation in participating member states relating to patents granted by the European Patent Office (EPO); national courts in...
#
Patenting
​
What languages does the UPC use?
01 November 2022
Central Division Proceedings at the central division are in the language in which the patent was granted (i.e., either French, German or English).
#
Patenting
​
IP considerations arising from increased micro mobility competition
24 June 2022
Following the Queen's Speech, and years of consultations and lobbying from the micro mobility sector, it looks like the e-scooter industry is in for a bumper year.
#
Patenting
​
Are open-source patent portfolios the key to the EV revolution?
16 June 2022
The widespread rollout of electric vehicles is viewed as a crucial part of the UK's green revolution. When discussing how this can be achieved, charging infrastructure is often cited as the key to...
#
Patenting
​
What is the likely timing of the UPC and UP coming into being?
09 June 2022
The Unified Patent Court (UPC) is currently completing preparations to be open for business (under the Protocol on the Provisional Application of the UPC Agreement (the ‘PAP-Protocol')).
#
Litigation
​
The Unitary Patent System is on the way
20 January 2022
We reported last year that the Unitary Patent and Unified Patent Court (UPC) were progressing. The main hurdle left to clear was sufficient countries ratifying the Protocol on the Provisional...
#
Litigation
​
Hybrid event: Healthcare Innovation & Strategy Series - IP Strategy Beyond Drafting Patents
19 October 2021
We would like to invite you to join us for the second part of our life science and medtech event on 09 November where we will continue to explore upcoming trends in IP and healthcare.
#
Patenting
​
Unlocking healthcare with AI
16 September 2021
Much has been written about the development of artificial intelligence (AI) and its potential to reshape everyday life.This potential is already being realised in healthcare, with health...
#
Patenting
​
License to heal
07 September 2021
The hallmark of 5G is extremely low latency speeds. In theory, robotics could be controlled from long distances with just 0.1 seconds of a delay.
#
Patenting
​
Ask the Experts: What can I do if someone is using my invention without my permission?
02 September 2021
In the previous articles, we looked at the mechanics of filing a patent application. In this last article of our ‘Ask the Experts' series, we will be addressing some of the other ways in which a...
#
Patenting
​
The personalised healthcare boom
01 September 2021
Personalised healthcare is a fairly new term relating to technology that gives individuals effective healthcare based on their own unique attributes.
#
Patenting
​
Ask the Experts: How can I manage the costs of a patent?
24 August 2021
In previous articles, we addressed the questions of whether applying for a patent is appropriate, and if so, when this should be done. This article addresses questions around the process for filing a...
#
Patenting
​